Dr. Kara Choate, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2021 N Macarthur Blvd Ste 450, Irving, TX 75061 Phone: 866-367-8768 |
Keith A Waguespack, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2021 N Macarthur Blvd Ste 450, Irving, TX 75061 Phone: 866-367-8768 Fax: 817-541-9301 |
Lawrence J Alter, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 7200 State Highway 161, Suite 200, Irving, TX 75039 Phone: 817-303-4521 Fax: 972-401-4930 |
William A Smith Jr., MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2021 N Macarthur Blvd, Ste 325, Irving, TX 75061 Phone: 972-253-4210 Fax: 972-253-2510 |
Zachary Robinson Compton, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2021 N Macarthur Blvd Ste 450, Irving, TX 75061 Phone: 866-367-8768 Fax: 817-541-9301 |
Keith D Bloom, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2021 N Macarthur Blvd Ste 450, Irving, TX 75061 Phone: 866-367-8768 Fax: 817-541-9301 |
News Archive
CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA). CytRx holds the exclusive worldwide development and commercialization rights to INNO-206.
Young adults with such cardiac risk factors as high blood pressure and elevated glucose levels have significantly worse cognitive function in middle age, according to a new study by dementia researchers at UC San Francisco.
Siblings of people with autism show a similar pattern of brain activity to that seen in people with autism when looking at emotional facial expressions. The University of Cambridge researchers identified the reduced activity in a part of the brain associated with empathy and argue it may be a 'biomarker' for a familial risk of autism.
Transcatheter heart valve company CardiAQ Valve Technologies (CVT), which is developing the world's first self-conforming and self-anchoring technology for Transcatheter Mitral Valve Implantation (TMVI), announced today that successful results of an acute in vivo study of its TMVI system were disclosed by Dr. Joseph Bavaria during the "Mitral Valve Therapies Prior to and in Human Investigation" program at the "Transcatheter Cardiovascular Therapeutics (TCT) 2009" annual scientific meeting on Friday.
› Verified 8 days ago